Return to search results
Patent AT-E399565-T1: [Translated] COMPOSITIONS FOR THE RAPID AND NON-IRRITATIVE TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHODS OF FORMULATION AND ADMINISTRATION THEREOF
A transdermal delivery system (TDS)for use in treatment of living bodies may be applied as an open (liquid, gel) or closed (patch) article. The TDS is composed of a particular active agent which dictates an associated selection of certain solvents, solvent modifiers, solute modifiers and skin stabilizers with which the medicament forms a true solution that rapidly crosses the skin barrier. The associated selection of the particular solvents, solvent modifiers, solute modifiers and skin stabilizers is based on a balancing of the molecular properties of all the components against the molecular properties of all the components plus the particular active agent. The TDS may also include a source of cellular energy to induce CAMP or cGMP. The TDS improves delivery of active agents having a molecular weight greater than 340 Daltons and increases dosage above 0.25 mg/day for such active agents.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| bureauCode |
[ "009:25" ] |
| contactPoint |
{ "fn": "NIH/NCBI Data Team", "@type": "vcard:Contact", "hasEmail": "mailto:info@ncbi.nlm.nih.gov" } |
| description | A transdermal delivery system (TDS)for use in treatment of living bodies may be applied as an open (liquid, gel) or closed (patch) article. The TDS is composed of a particular active agent which dictates an associated selection of certain solvents, solvent modifiers, solute modifiers and skin stabilizers with which the medicament forms a true solution that rapidly crosses the skin barrier. The associated selection of the particular solvents, solvent modifiers, solute modifiers and skin stabilizers is based on a balancing of the molecular properties of all the components against the molecular properties of all the components plus the particular active agent. The TDS may also include a source of cellular energy to induce CAMP or cGMP. The TDS improves delivery of active agents having a molecular weight greater than 340 Daltons and increases dosage above 0.25 mg/day for such active agents. |
| distribution |
[ { "@type": "dcat:Distribution", "title": "Official Data Source", "mediaType": "text/html", "description": "Access the complete Patent AT-E399565-T1: [Translated] COMPOSITIONS FOR THE RAPID AND NON-IRRITATIVE TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHODS OF FORMULATION AND ADMINISTRATION THEREOF on the official website.", "downloadURL": "https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399565-T1" } ] |
| identifier | https://healthdata.gov/api/views/5pya-w955 |
| issued | 2025-09-05 |
| keyword |
[ "chemistry", "innovation", "patent", "pubchem", "research" ] |
| landingPage | https://healthdata.gov/d/5pya-w955 |
| modified | 2025-09-06 |
| programCode |
[ "009:066" ] |
| publisher |
{ "name": "National Center for Biotechnology Information (NCBI)", "@type": "org:Organization" } |
| theme |
[ "NIH" ] |
| title | Patent AT-E399565-T1: [Translated] COMPOSITIONS FOR THE RAPID AND NON-IRRITATIVE TRANSDERMAL ADMINISTRATION OF PHARMACEUTICALS AND METHODS OF FORMULATION AND ADMINISTRATION THEREOF |
